HIV I Infection Clinical Trial
Official title:
Leveraging Family-Based Assets for Black MSM In House Ball Communities (Our Family, Our Voices-"OFOV)
Verified date | September 2021 |
Source | State University of New York - Downstate Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Despite the advent of highly effective prevention tools such as HIV pre-exposure prophylaxis (PrEP), Black men who have sex with men (MSM) continue to have the highest incidence of new HIV diagnoses in the US but are least likely to be engaged in care or to be virally suppressed. Many Black MSM face multiple stigmas but some have found refuge in the House Ball Community (HBC)-a national network of Black LGBT kinship commitments (families) that provide (informal) care giving, affirmation and survival skills-building for its members. The HBC is a large, yet underserved, community within the larger LGBT community. The investigators propose to modify a well-established skills-building and HIV prevention best-evidence, group-level intervention for HIV-negative Black MSM, Many Men Many Voices, into a family-based intervention to focus on asset-building for both HIV-negative and HIV-positive Black MSM within HBC families. Many Men Many Voices (3MV) is a six-session, group-level behavioral intervention and is the only "best evidence" intervention for Black MSM. Family-based interventions have shown HIV prevention efficacy; however, 3MV is not a family-based intervention. In 3MV, HIV-negative Black MSM are recruited into artificial group settings with individuals with whom they may have little social relationship. 3MV neither leverages the connections and commitments nor addresses the variability in HIV-status that exists in house ball families. Because Black MSM in the HBC have closer social relationships, 3MV requires adaptation to be more responsive to this social structure and dynamic. The study's goal in this clinical trial planning grant is to prepare for a cluster randomized controlled trial (CRCT) to test the effectiveness of the modified 3MV vs. standard of care in reducing new HIV infections and increasing rates of viral suppression among Black MSM in HBC families. The study's central hypothesis is that a modified 3MV intervention incorporating family asset-building will have an amplifying effect on HIV prevention and treatment outcomes. This study will provide necessary data to design and conduct a full-scale CRCT effectiveness trial of OFOV on HIV prevention and care outcomes in Black MSM. By precision-tailoring an evidence-based intervention for the HBC, the investigators' research to improve HIV testing and care engagement will complement national efforts to End the Epidemic by 2030, especially among Black MSM-the highest priority group for domestic HIV prevention.
Status | Enrolling by invitation |
Enrollment | 168 |
Est. completion date | November 30, 2021 |
Est. primary completion date | November 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility | Inclusion Criteria: - Eligibility for the study will be determined primarily at the family-level. At least 12 members of the same HBC family must be willing to participate together, of which at least half the participating members must be Black MSM. Participating family members must reside in the New York City metro area. Black MSM participants must be at least 18 years old. Exclusion Criteria: - Not being a member of a house ballroom community family - Residing outside the New York City - Being a member of a house ballroom community family that has been established less than 12 months |
Country | Name | City | State |
---|---|---|---|
United States | HEAT Program/SUNY Downstate Medical Center | Brooklyn | New York |
Lead Sponsor | Collaborator |
---|---|
State University of New York - Downstate Medical Center | National Institute of Mental Health (NIMH), Yale University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HIV testing | primary outcome for HIV-negative participants: the change in the proportion of those who are HIV-negative having been tested for HIV at the three time point s | measured at time 0, 3 months and 6 months | |
Primary | HIV testing | primary outcome for HIV-negative participants: total change in the number of HIV test results among those who are HIV-negative and have been tested for HIV at the 3 time points | measured at time 0, 3 months and 6 months | |
Primary | PrEP use | primary outcome for HIV-negative participants: the change in the proportion of those who are HIV-negative who report taking PrEP at the three time points | measured at time 0, 3 months and 6 months | |
Primary | HIV care engagement | primary outcome for participants living with HIV: the change in the proportion of those living with HIV who report medical visits at the three time points | measured at time 0, 3 months and 6 months | |
Primary | Taking ARV treatment | primary outcome for participants living with HIV: the change in the proportion of those living with HIV who report taking ARV treatment at the three time points | measured at time 0, 3 months and 6 months | |
Primary | Viral load measurement | primary outcome for participants living with HIV: the change in the proportion of those living with HIV with undetectable HIV viral loads among those taking ARV treatment at the 3 time points | measured at time 0, 3 months and 6 months | |
Secondary | Family based assets 1: Sense of Community Scale | The change in the aggregate scores of all study participants across the 3 times points as a secondary measurement to study impact of the intervention | measured at time 0, 3 months and 6 months | |
Secondary | Family based assets 2: READY Tool | The change in the aggregate scores of all study participants across the 3 times points as a secondary measurement to study impact of the intervention | measured at time 0, 3 months and 6 months | |
Secondary | Family based assets 3: Asset Inventory | The change in the Asset Inventory scores of all study participants across the 3 times points as a secondary measurement to study impact of the intervention | measured at time 0, 3 months and 6 months | |
Secondary | Brief Resilience Scale | The change in the aggregate scores of all study participants across the 3 times points as a secondary measurement to study impact of the intervention | measured at time 0, 3 months and 6 months | |
Secondary | Condomless anal intercourse | The change in the relative frequency = # times condoms used during anal sex / total # episodes of anal sex in the past 3 months among all study participants across the 3 times points as a secondary measurement to study impact of the intervention | measured at time 0, 3 months and 6 months | |
Secondary | Number of sexual partners | The change in the total number of sexual partners in the past 3 months among all study participants across the 3 times points as a secondary measurement to study impact of the intervention | measured at time 0, 3 months and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04585737 -
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
|
Phase 4 | |
Not yet recruiting |
NCT06282783 -
Studying Topiramate for Re-Activating the HIV-1 Reservoir
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03622177 -
Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection
|
||
Recruiting |
NCT05854381 -
To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV
|
Phase 1 | |
Completed |
NCT05421806 -
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
|
||
Completed |
NCT04568395 -
Acute Effects of TCIG vs ECIG in PLWH
|
N/A | |
Recruiting |
NCT04887675 -
Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI
|
N/A | |
Recruiting |
NCT04820933 -
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
|
Early Phase 1 | |
Completed |
NCT03584048 -
Charlotte Retention in Care Study
|
||
Recruiting |
NCT06005610 -
Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
|
Phase 2 | |
Recruiting |
NCT05947890 -
Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa
|
Phase 2 | |
Recruiting |
NCT05187429 -
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05601128 -
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
|
Phase 3 | |
Completed |
NCT04675255 -
Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism
|
N/A | |
Recruiting |
NCT05110963 -
Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments
|
N/A | |
Completed |
NCT03986099 -
Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART
|
N/A | |
Completed |
NCT04971343 -
Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
|
||
Completed |
NCT04725877 -
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04618198 -
Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT05383456 -
The Visceral Adiposity Measurement and Observation Study
|